8-K: FOXO Technologies Secures Shareholder Approval for Key Proposals Including Reverse Stock Split and Debt Conversion

FOXO Technologies Inc. announced the successful outcome of its Special Meeting of Shareholders, with all proposed resolutions receiving the necessary approvals.

Summary

• FOXO Technologies held a Special Meeting of Shareholders on November 29, 2024, where several key proposals were voted on.
• A total of 16,773,176 shares, representing 93.859% of outstanding Class A common stock, were present either in person or by proxy, establishing a quorum.
• Shareholders approved a reverse stock split, with a ratio ranging from 1:5 to 1:100, to be determined by the Board of Directors before September 30, 2025, though the board may elect not to complete the split if the share price improves.
• The company received approval to issue shares for debt conversion with a debt holder, with the debt outstanding at approximately $1,945,000 as of September 30, 2024.
• Shareholders also approved the issuance of shares related to a $5 million Equity Line of Credit with ClearThink Capital Partners, LLC.
• Additionally, approval was granted for the issuance of shares related to a $2.5 million debt funding agreement with an institutional investor, of which $1 million has already been received.
• All proposals, including the adjournment of the meeting if necessary, were approved by a majority of votes cast.

Sentiment

Score: 6

Explanation: The document reflects a mix of positive and negative elements. While shareholder approval was secured for key proposals, the need for a reverse stock split and debt conversion indicates underlying financial challenges. The company is taking steps to address these challenges, but the risks remain.

Positives

• The company successfully obtained shareholder approval for all key proposals, indicating strong shareholder support.
• The approval of the reverse stock split provides flexibility to address potential listing compliance issues.
• The debt conversion and equity line of credit provide the company with additional financial resources.
• The company has secured $1 million in debt funding, with a further $1.5 million available.

Negatives

• The need for a reverse stock split suggests the company's share price was at risk of falling below the NYSE American minimum requirement of $0.10.
• The company has been unable to repay a debt holder, necessitating a debt-for-equity swap.
• The company is relying on an equity line of credit and debt funding, indicating potential financial challenges.

Risks

• The company's share price may still fall below the $0.10 minimum requirement for NYSE American continued listing.
• The company may not be able to draw on the full $5 million equity line of credit.
• The company may not be able to convert the full $2.5 million debt funding into equity.
• The company faces risks related to the competitive and regulated industries in which it operates.
• The company has a history of losses and may not achieve or maintain profitability in the future.

Future Outlook

The company anticipates that the approved proposals will provide the necessary financial flexibility to support its business objectives and create value for shareholders, while also acknowledging the risks associated with the competitive and regulated industries in which it operates.

Management Comments

• We sincerely appreciate the support our shareholders continue to provide, said Mark White, Interim CEO of FOXO, to have almost 94% of our shareholders vote on these matters was an exceptional result.
• We look forward to the opportunities the transformation of our Company throughout 2024 has presented, and believe we can create significant value for our shareholders as we build on these opportunities.

Industry Context

The announcement reflects the challenges faced by some companies in maintaining listing compliance on exchanges like NYSE American, and the need to explore various financing options, including debt conversion and equity lines of credit. The biotechnology industry is highly competitive and regulated, requiring companies to be proactive in managing their financial health.

Comparison to Industry Standards

• Reverse stock splits are a common strategy for companies facing delisting risks, similar to actions taken by other small-cap companies in the biotech sector.
• Debt-for-equity swaps are frequently used by companies with high debt burdens, a strategy also seen in other industries facing financial difficulties.
• Equity lines of credit are a common financing tool for companies seeking flexible access to capital, similar to arrangements used by other growth-stage companies.
• The need to issue shares to raise capital is a common practice in the biotech industry, where companies often require significant funding for research and development.

Stakeholder Impact

• Shareholders have approved key proposals that will impact the company's capital structure.
• The company's employees may be impacted by the company's financial situation and future plans.
• The company's customers and suppliers may be impacted by the company's financial situation and future plans.
• The company's creditors may be impacted by the company's financial situation and future plans.

Next Steps

• The Board of Directors will determine the exact ratio for the reverse stock split before September 30, 2025.
• The company will proceed with the debt-for-equity swap with the debt holder.
• The company may draw on the $5 million Equity Line of Credit as needed.
• The company will continue to work with the institutional investor to receive the remaining $1.5 million in debt funding.

Key Dates

Keywords

reverse stock split, debt conversion, equity line of credit, shareholder approval, NYSE American, debt funding, Class A Common Stock, special meeting, listing requirements